Grant Award Details
- Using 8 approved drugs (3 M1 antagonists, 3 VDR agonists, bexarotene, tamoxifen), to identify a 2-drug combination (development candidate) with improved efficacy and tolerability as compared to monotherapies in a rodent remyelination model.
Grant Application Details
- Improving the efficacy and tolerability of clinically validated remyelination-inducing molecules using developable combinations of approved drugs
The candidate is a fixed dose binary small molecule drug combination, consisting of two agents that act synergistically on a multipotent stem cell population in the CNS to stimulate remyelination.
The proposed studies will address bottleneck issues related to the effect size and tolerability of clinically validated remyelination drug classes.
Major Proposed Activities
- Establish the maximal and minimal effective concentrations (ECmin and ECmax) and associated levels of efficacy for defined combination-based drug therapies in three populations of rat OPCs.
- Establish maximal and minimal effective concentrations and associated levels of efficacy for defined drug combinations in a population of human OPCs.
- Demonstrate reproducible disease modifying activity (i.e., enhancement of remyelination efficiency) in vivo using the cuprizone model of demyelination/remyelination.
- Complete mouse brain pharmacokinetic (PK), drug-drug interaction and preliminary rodent tolerability studies for 3 OPC differentiation-inducing drug combinations.
- Complete mechanism of action studies
- Complete penultimate in vivo efficacy study with kinetic measures and imaging outputs using the cuprizone model of demyelination/remyelination.
It is estimated that >120,000 California residents suffer from multiple sclerosis (MS). This proposed research aims to provide a disease modifying therapy for MS. It will have a significant beneficial impact, by targeting the regenerative process known as remyelination, which becomes limiting during the progressive phases of MS disease.